FDA's Guide: How We Peek into Your Lipstick Lab Records
Published Date: 1/22/2026
Notice
Summary
The FDA just dropped a draft guide to help cosmetic companies understand how the agency can check their product records. If you make or sell cosmetics, this guide explains what info the FDA might ask for and how the process works. You’ve got until March 23, 2026, to share your thoughts before the FDA finalizes the rules—no extra costs yet, just clear steps ahead!
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
FDA can copy records if SAHCODH suspected
Under section 610 (21 U.S.C. 364f), if FDA reasonably believes a cosmetic (or an ingredient) is likely adulterated and presents a threat of serious adverse health consequences or death (SAHCODH), FDA may access and copy certain records. The draft guidance explains how FDA applies that authority and what records may be copied.
Inspection authority extended to manufacturer records
Section 704(a)(1) of the FD&C Act, as amended by MoCRA (section 3504), extends FDA's inspectional authority to all records and information described in sections 605 and 610 from facilities that manufacture and process cosmetic products. The draft guidance discusses how that expanded inspection authority is applied.
FDA access to adverse event records
If you make or sell cosmetics, FDA can access adverse event records during an inspection under section 605 (21 U.S.C. 364a) and section 704 of the FD&C Act. The draft guidance explains FDA's criteria, process, and expectations for that access.
Draft guidance available — comment deadline
The FDA released a draft guidance titled "FDA Records Access Authority for Cosmetics: Guidance for Industry" and is asking for comments. You may submit electronic or written comments by March 23, 2026; the guidance is not binding and explains FDA's current thinking on criteria, process, and expectations.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2026-01158, Medical Review Board; Membership
The Department of Transportation is looking for new members to join the Medical Review Board, which gives expert medical advice about truck driver health rules. If you or someone you know works in medicine and wants to help shape safety standards for commercial drivers, now’s the time to apply! Nominations are due by February 23, 2026, and there’s no cost to join—just a chance to make a big impact.
Next: 2026-01160, Procurement List; Additions
Starting February 1, 2026, new services will be added to the government’s Procurement List, meaning federal agencies must buy these services from nonprofit groups that employ people who are blind or have severe disabilities. This change helps support these nonprofits without adding extra paperwork or costs. It’s a win-win for the government and amazing workers making a difference!